Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion.
1. To investigate the metabolites and biliary excretion of new camptothecin analogue, irinotecan, the drug was administered i.v. to rats (10 mg/kg) and bile, urine and faeces were collected. 2. In rat bile, unchanged irinotecan, the metabolite 7-ethyl-10-hydroxycamptothecin (EHCPT) and unknown metabolite M-1 were found by t.l.c. and h.p.l.c. From beta-glucuronidase hydrolysis, n.m.r. spectrometry and mass spectrometry, M-1 was identified as EHCPT-glucuronide (EHCPT Glu). Other metabolites in the bile were negligible. 3. The cumulative biliary and urinary excretion of radioactivity after dosage of rats with irinotecan were 62.2% and 33.3% dose, respectively, and 9.0% of the radioactivity was excreted in the faeces. 4. Approx. 55% of the biliary radioactivity excreted in 24 h was unchanged irinotecan, 22% was EHCPT Glu, and 9% was EHCPT. 5. Approx. 18% of the biliary radioactivity was reabsorbed from the intestine.
Atsumi
R
R
Research Institute, Daiichi Pharmaceutical Co. Ltd, Tokyo, Japan.
Suzuki
W
W
Hakusui
H
H
D000818:Animals; D001646:Bile / Q000737:chemistry / Q000378:metabolism*; D001711:Biotransformation; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000378:metabolism* / Q000493:pharmacokinetics / Q000633:toxicity; D002851:Chromatography, High Pressure Liquid; D002855:Chromatography, Thin Layer; D004764:Enterohepatic Circulation; D005243:Feces / Q000737:chemistry; D005966:Glucuronidase; D006868:Hydrolysis; D007410:Intestinal Diseases / Q000139:chemically induced; D000077146:Irinotecan; D007783:Lactones / Q000378:metabolism; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D013058:Mass Spectrometry; D051381:Rats; D011919:Rats, Inbred Strains; D013050:Spectrometry, Fluorescence
D007783:Lactones; D000077146:Irinotecan; D005966:Glucuronidase; D002166:Camptothecin